Defining high risk prostate cancer with risk groups and nomograms: implications for designing clinical trials.
about
Pre-treatment risk stratification of prostate cancer patients: A critical review.High-risk prostate cancer-classification and therapy.Favorable outcomes in locally advanced and node positive prostate cancer patients treated with combined pelvic IMRT and androgen deprivation therapyCurrent prostate cancer: 20 years later.Predictive models in external beam radiotherapy for clinically localized prostate cancer.Multidisciplinary intervention of early, lethal metastatic prostate cancer: Report from the 2015 Coffey-Holden Prostate Cancer Academy Meeting.Heterogeneity in high-risk prostate cancer treated with high-dose radiation therapy and androgen deprivation therapyNew tricks with old dogs: personalised medicine and clinical trialsPET and PET/CT with radiolabeled choline in prostate cancer: a critical reappraisal of 20 years of clinical studies.Allelic loss of the loci containing the androgen synthesis gene, StAR, is prognostic for relapse in intermediate-risk prostate cancer.The number of risk factors is the strongest predictor of prostate cancer mortality: multi-institutional outcomes of an extreme-risk prostate cancer cohort.Fatigue and other adverse effects in men treated by pelvic radiation and long-term androgen deprivation for locally advanced prostate cancer.Adding intensity-modulated radiotherapy to the pelvis does not worsen the adverse effect profiles compared to limited field radiotherapy in men with prostate cancer at 12-month follow-up.Intensity-modulated radiotherapy to the pelvis and androgen deprivation in men with locally advanced prostate cancer: a study of adverse effects and their relation to quality of life.Copy number alterations of c-MYC and PTEN are prognostic factors for relapse after prostate cancer radiotherapy
P2860
Q34268868-F5DFCA1A-7937-4A18-ACF3-2F148EB0FE85Q35869811-F986EE9C-34A3-4F59-B0D8-D9515F56627CQ36293177-CACBFBD8-5CC2-4A0E-B2B5-99F75C553901Q36861729-B6D2CE8E-1B53-4035-AD71-7945EC70A1CBQ37526758-FBC29BB7-2C4D-43E9-BD78-FE133BC2E5D7Q38610286-DE90C861-8704-4746-A0CC-C0A5B678704FQ38648500-80E84634-588C-4244-A5E1-27DA2A186D37Q38650321-04AB35F1-8EBB-4256-94F4-B4F59228DC6AQ39242140-69D89356-F16B-40C2-8EED-B1C7001C306CQ39668407-2C013ED3-5977-4EEA-9940-14039C0A2639Q40967893-ED71F5AC-4A2B-4C09-838B-18056A88623AQ47802807-71E60661-9C20-4478-9A5E-486248ECF265Q48075929-A25EA780-EAED-4032-9234-CFE75AD65E4AQ48271324-708A74A3-DEB3-4199-BBDB-AEC83370D47FQ57790286-C432B407-3CAB-4F87-AABC-70BAC40159EA
P2860
Defining high risk prostate cancer with risk groups and nomograms: implications for designing clinical trials.
description
2006 nî lūn-bûn
@nan
2006年の論文
@ja
2006年学术文章
@wuu
2006年学术文章
@zh
2006年学术文章
@zh-cn
2006年学术文章
@zh-hans
2006年学术文章
@zh-my
2006年学术文章
@zh-sg
2006年學術文章
@yue
2006年學術文章
@zh-hant
name
Defining high risk prostate ca ...... for designing clinical trials.
@en
Defining high risk prostate ca ...... for designing clinical trials.
@nl
type
label
Defining high risk prostate ca ...... for designing clinical trials.
@en
Defining high risk prostate ca ...... for designing clinical trials.
@nl
prefLabel
Defining high risk prostate ca ...... for designing clinical trials.
@en
Defining high risk prostate ca ...... for designing clinical trials.
@nl
P2093
P1476
Defining high risk prostate ca ...... for designing clinical trials.
@en
P2093
H M Sandler
M W Kattan
P W McLaughlin
V Weinberg
P304
P356
10.1016/J.JURO.2006.06.081
P407
P433
P50
P577
2006-12-01T00:00:00Z